RE:COVID-19 and PMX treatmentYes it's interesting
Another thought on this....
Canada has lost roughtly 31,000 pepple to Covid-19, since the start of the pandemic.
Prior to Covid, the Cdn annual death rate due to
Sepsis was about 30,000.*
So has Covid-19 now in effect, doubled the number of Sepsis-like deaths?
*This makes sense when comparing to CDA numbers for the US using 2017? stats...and Canada is a little more than 10% of the population of the US (38M vs 350M)
What is sepsis? | Sepsis | CDC -
At least 1.7 million adults in America develop sepsis.
-
Nearly 270,000 Americans die as a result of sepsis.
-
1 in 3 patients who dies in a hospital has sepsis.
-
Sepsis, or the infection causing sepsis, starts outside of the hospital in nearly 87% of cases.
My question is, of course, if Covid deaths persist, and it leads to an increased incidence of endotoxemia , MOF, and death as a result, wouldn't future PMX revenue targets go up commensuarably? Double? 50%?
Even if Covid becomes less severe, or it becomes a milder Endemic (not known), many will point to long Covid and the hidden, and not so hidden LT organ damage done to past hosptilaized patients who are now at increased risk of Sepsis going forward. And many of the survirvors have suffered permanent kidney damage (AKI ) and will need dialysis for the rest of their lives (Dialco upside as well?)
No proven link/benefit of PMX for severe Covid patients you say? Not according to a recent Ronco, Kellum video discussions and any reasonable review of the currently available medical reporting/research on the subject. Even if tenuous, it should be talked about and floated as a possiblity. IMO it is not that tenuous.
Last I checked, when a company's future revenues are likely to
increase materially, for whatever reason, the Company Management
talks about it (as part of their fiduciary duty to
enhance shareholder value), with the indirect benefit of causing their stock price to incease in value (with the added benefit of less dilutive future cash raises).
MM